A new vaccine to prevent Alzheimer's disease by targeting harmful proteins in the brain.
Official title: Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
Funded at Nuravax, INC. · NIH-11067040 · Data updated 2026-11-12
This study is testing a new vaccine called Duvax that aims to help the immune system clear away harmful proteins linked to Alzheimer's disease, and it's looking for healthy volunteers to see how safe it is and how well it works in preventing memory problems later on.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nuravax, INC. NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $499,754 |
| NIH project number | 1R44AG091903-01 |
| Project ID | NIH-11067040 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are healthy adults aged 21 and older who are at risk for developing Alzheimer's disease.
✕Less likely to help
Patients who are already diagnosed with Alzheimer's disease or have significant cognitive impairment may not benefit from this research.
What this research studies
This research investigates a dual vaccine called Duvax, designed to target and reduce the accumulation of harmful proteins associated with Alzheimer's disease, specifically beta-amyloid and tau. The vaccine aims to stimulate the immune system to recognize and eliminate these proteins, potentially delaying the onset of Alzheimer's symptoms. Healthy volunteers will be involved in evaluating the safety, tolerability, and immune response generated by this innovative vaccine. The study will follow participants over time to assess the vaccine's effectiveness in preventing cognitive decline.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking preventive treatment for Alzheimer's disease, potentially delaying or preventing the onset of dementia.
How similar studies have gone: While there have been various approaches to targeting Alzheimer's pathology, this dual vaccine approach is relatively novel and has not been extensively tested in previous studies.
Where this research is happening
-
Nuravax, INC.
Irvine, United States Active
Researchers
- Principal investigator: Cribbs, David Hastings — Nuravax, INC.
- Study coordinator: Cribbs, David Hastings
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.